

Factsheet FY/20



COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 311,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	FY/20	FY/19	Change
Sales and Earnings			
Sales	36,277	35,409	2%
EBIT ¹	4,612	4,631	-2%
Net income ^{1,2}	1,796	1,879	-4%
Earnings per ord. share in € ^{1,2}	3.22	3.37	-4%
Balance sheet and cash flow			
Total assets ³	66,646	67,006	-1%
Non-current assets ³	50,874	51,742	-2%
Equity ³	26,023	26,580	-2%
Equity ratio ³	39.0%	39.7%	-
Net debt/EBITDA ^{1,4}	3.44	3.61	--
Investments ⁵	3,300	5,086	-35%
Operating cash flow	6,549	4,263	54%
Operating cash flow in % of sales	18.1%	12.0%	--
Profitability			
EBIT margin ¹	12.7%	13.2%	--
Return on equity after taxes (ROE) ^{1,2}	10.6%	11.2%	--
Return on operating assets (ROOA) ¹	7.3%	7.6%	--
Return on invested capital (ROIC) ¹	6.5%	6.7%	--
Employees	311,269	294,134	6%

¹ Before special items

² Net income attributable to shareholders of Fresenius SE & Co. KGaA

³ Including noncontrolling interests


⁴ LTM average exchange rates for both net debt and EBITDA;

pro forma closed acquisitions/divestitures

⁵ Investments in property, plant and equipment, and intangible assets, acquisitions

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.



¹ As of December 31, 2020

BUSINESS SEGMENTS


€ in millions		FY/20	FY/19	Change
FRESENIUS MEDICAL CARE	Sales	17,859	17,477	2%
	EBIT ¹	2,304	2,270	2%
FRESENIUS KABI	Sales	6,976	6,919	1%
	EBIT ²	1,095	1,205	-9%
FRESENIUS HELIOS	Sales	9,818	9,234	6%
	EBIT	1,025	1,025	0%
FRESENIUS VAMED	Sales	2,068	2,206	-6%
	EBIT	29	134	-78%

¹ Reported


² Before special items

- ▶ **Fresenius Medical Care** is the world's largest provider of products and services for individuals with renal diseases. As of December 31, 2020 Fresenius Medical Care was treating 346,553 patients in 4,092 dialysis clinics. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care.
- ▶ **Fresenius Kabi** offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients. The company is also a leading supplier of medical devices and transfusion technology products. In the biosimilars business, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases.
- ▶ **Fresenius Helios** is Europe's leading private hospital operator. Helios Germany operates 89 acute care hospitals, ~130 outpatient clinics and 6 prevention centers. Quirónsalud operates 52 hospitals, including 6 in Latin America, 70 outpatient centers and around 300 occupational risk prevention centers.
- ▶ **Fresenius Vamed** manages projects and provides services for hospitals and other health care facilities worldwide and is a leading post-acute care provider in Central Europe. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management to total operational management.

SALES BY REGION




SALES BY BUSINESS SEGMENT




FRESENIUS SHARE / ADR

	Share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (December 31, 2020)	557,540,909
Market capitalization (December 31, 2020)	€21.1 billion


RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX




ANALYST RECOMMENDATIONS



FINANCING MIX OF THE FRESENIUS GROUP



DEVELOPMENT OF DIVIDENDS IN €



¹ Proposal

GROUP OUTLOOK 2021

	FY/20 Base ¹	Targets 2021 ²
Sales, growth (cc)	€36,277 million	Low-to-mid single-digit percentage growth
Net income ³ , growth (cc)	€1,796 million	At least broadly stable

¹ Before special items, including COVID-19 effects

² Before special items, including estimated COVID-19 effects

³ Net income attributable to shareholders of Fresenius SE & Co. KGaA

For the outlook of the business segments please see the Investor News of February 23, 2021.

FINANCIAL CALENDAR

	Dates
Report on 1st quarter 2021	May 6, 2021
Annual General Meeting	May 21, 2021
Payment of dividend ¹	May 27, 2021
Report on 2nd quarter 2021	July 30, 2021
Report on 3rd quarter 2021	November 2, 2021

Schedule updates, information on live webcasts, and other events at www.fresenius.com/events-and-roadshows

¹ Subject to prior approval by the Annual General Meeting

CONTACT

Fresenius SE & Co. KGaA

Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.

e-mail: ir-fre@fresenius.com

Internet: www.fresenius.com

Markus Georgi

Senior Vice President

Investor Relations & Sustainability

Telephone: +49 61 72 6 08-24 85

Telefax: +49 61 72 6 08-24 88

Follow us:

